The implant mimics the natural motion of a native disc and is indicated as an alternative to cervical fusion. It received FDA approval in 2019 and also has a CE mark in the European union.
Earlier this year, three- and four- year data showed the effectiveness of M6-C at the single level, and a U.S. investigational device exemption two-level study began in August.
“The M6-C artificial cervical disc is continuing to establish a market-leading position globally with more than 60,000 devices implanted worldwide,” Orthofix President of Global Spine Kevin Kenny stated in a news release from the company. “We are pleased to see the continued adoption of this state-of-the-art technology as our international success translates into the U.S. market.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
